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ABSTRACT
Wogonin, a flavonoid derived from Scutellaria baicalensis Georgi, has been 
demonstrated to be highly effective in treating hematologic malignancies. In this 
study, we investigated the anticancer effects of wogonin on K562 cells, K562 
imatinib-resistant cells, and primary patient-derived CML cells. Wogonin up-regulated 
transcription factor GATA-1 and enhanced binding between GATA-1 and FOG-1, 
thereby increasing expression of erythroid-differentiation genes. Wogonin also up-
regulated the expression of p21 and induced cell cycle arrest. Studies employing 
benzidine staining and analyses of cell surface markers glycophorin A (GPA) and CD71 
indicated that wogonin promoted differentiation of K562, imatinib-resistant K562, and 
primary patient-derived CML cells. Wogonin also enhanced binding between GATA-1 
and MEK, resulting in inhibition of the growth of CML cells. Additionally, in vivo studies 
showed that wogonin decreased the number of CML cells and prolonged survival of 
NOD/SCID mice injected with K562 and imatinib-resistant K562 cells. These data 
suggested that wogonin induces cycle arrest and erythroid differentiation in vitro 
and inhibits proliferation in vivo.
INTRODUCTION
The K562 cells were derived from a patient suffering 
from chronic myelogenous leukemia (CML) blast crisis 
phase and used as the cell line for the research of erythroid 
differentiation[1, 2]. Erythroid differentiation is a process 
of formation of red blood cells in the bone marrow is a 
highly regulated event. The erythrocytes are formed 
from progenitor cells which is potent to differentiate 
into erythroid or megakaryocyte lineages. CML is a 
comprehensive investigation disease. It is a paradigm 
for neoplasias that evolve through a muti-step process.
[3] Patients enter an chronic phase (CP) at first, and then 
enter an accelerated phase (AP), followed by a blast 
crisis (BC) during which hematopoietic differentiation 
becomes arrested[4]. BCR-ABL is a fusion oncogene 
which encodes tyrosine kinase that is important for the 
activation of the proliferation and survival pathway[4, 5]. 
BCR-ABL has been verified to be the causative agent of 
CML. It is generated by the t(9;22)(q34;q11). Imatinib 
is a BCR-ABL kinase inhibitor which blocks the growth 
of BCR-ABL-transformed cells, and is effective in 
disease remission in chronic phase CML patients [6-8]. 
However, resistance to imatinib develops that ultimately 
leads to disease progression[9]. Recently, results from 
the ‘non-randomized stop IM’ trial showed that 61% of 
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CML patients who discontinued imatinib after achieving 
a complete molecular remission eventually relapsed [10-
12]. Therefore, a great deal of attention has been paid 
to develop alternative molecular-based strategies for 
treatment of imatinib-resistant CML. 
GATA-1 is a zinc finger transcription factor that 
induces the differentiation of megakaryocytes and 
erythrocytes, and is required for mast cell and eosinophil 
development[13, 14]. Recent studies have found that 
GATA-1 directly represses transcription of numerous 
genes (including GATA-2 and c-Kit), and inhibits cell 
division during terminal hematopoietic differentiation 
[15, 16]. It is reported that GATA-1 plays critical roles 
for granulocyte/monocyte (GM) and megakaryocyte/
erythrocyte (MegE) lineage commitment. GATA-1 is 
critical for the development of megakaryocytes and 
erythroid cells[17-19]. In addition to GATA-1, Friend 
of GATA-1 (FOG-1), is also required for differentiation 
of megakaryocytes and erythrocytes, where GATA-1 
is expressed, and collaborates with GATA-1 to induce 
erythroid differentiation [14, 17, 20]. Regulation of 
GATA-1 chromatin occupancy is critical for its control of 
hematopoietic lineage specification by FOG-1[14].
Wogonin is a natural flavonoid derived from a 
Chinese herb, Scutellaria baicalensis, and has been 
reported to induce differentiation of AML cells [21, 
22]. The ability to induce cell differentiation may be 
an important attribute for an anti-leukemia agent, and 
we therefore further explored the effects of wogonin on 
induction of differentiation in CML cells. We investigated 
the effect of inducing differentiation, cycle arrest and 
growth inhibition of wogonin on K562, K562 imatinib-
resistant cells (K562r), and primary patient-derived CML 
cells in vitro. Also we detected the anti-CML effect of 
wogonin in vivo. To further investigate the mechanism 
of wogonin in anti-CML effect, we studied the effect of 
wogonin on GATA-1. Our results about GATA-1 were 
consistent with those in previous reports, and it was 
possible that wogonin induced differentiation, arrested 
cell cycle and inhibited growth of CML cells by regulating 
GATA-1. Our data suggest that wogonin may be useful for 
clinical treatment of CML patients.
RESULTS
Effects of wogonin on K562 and K562r cell cycle 
and differentiation
According the pre-experiment, we applied wogonin 
in the concentrations of 20 μM, 40 μM, and 80 μM. 
Results showed that wogonin arrested cell cycle at the 
G0/G1 phase in K562 cells (Figure 1A-B). A 4-day 
incubation with wogonin exerted a dose-dependent effect 
on differentiation of K562 cells as judged by benzidine 
staining (Figure 1G). To further confirm the effect of 
wogonin on K562 cell differentiation, we examined the 
expression of GPA and CD71, two erythroid differentiation 
specific markers. As shown in Figure 1D and 1E, results 
showed that the numbers of GPA and CD71 positive 
cells increased following incubation with wogonin for 
96 hours. And the mRNA level of GPA increased (Figure 
1H). Additionally, the mRNA level of γ-globin increased, 
one erythroid differentiation relative gene, in the cells 
following incubation of wogonin for 96 hours. The dose-
dependent increase of γ-globin further demonstrated the 
differentiation inducing activity of wogonin in K562 cells 
(Figure 1I). These results indicated that wogonin induced 
differentiation and arresting cell cycle at G0/G1 phase in 
K562 cells.
Interestingly, we found the similar effect in imatinib-
resistant K562 (K562r) cells. Imatinib mesylate (Gleevec, 
STI571), a first generation oral BCR-ABL kinase 
inhibitor, blocks the growth of BCR-ABL -transformed 
cells, and is highly effective in inducing disease remission 
in chronic phase CML patients (remission rate > 90%)
[23, 24]. Unfortunately, the pre-existence of imatinib 
mesylate resistance ultimately leads to therapy failure[6, 
8]. Wogonin exerted its anticancer effects via a different 
mechanism from imatinib, suggesting the possible 
sensitivity of K562r cells. Wogonin arrested cell cycle at 
G0/G1 phase in K562r cells (Figure 1A, 1C). Benzidine 
staining, specific markers detection of GPA and CD71 and 
mRNA expression of GPA and γ-globin results showed 
the differentiation inducing activity of wogonin (Figure 
1D, 1F-I). These results showed that wogonin induced 
erythroid differentiation and arrest cell cycle in both K562 
and K562r cells. 
Effects of wogonin on GATA-1 regulation in K562 
and K562r cells
To further examine the mechenism of wogonin 
on K562 and K562r cells, we detected nuclear proteins 
expression in these two cell lines in the presence of 
wogonin for 0, 12, 24, 36, and 48 hours. Western blot 
analyses showed that levels of nuclear GATA-1 and FOG-
1 were increased in a dose-dependent manner following 
incubation with wogonin (Figure 2A). Moreover, cells 
treated with 20, 40, and 80 µM wogonin for 48 hours 
showed a dose-dependent increase in DNA binding of 
GATA-1 (Figure 2B). It has been reported that FOG-
1 and GATA-1 are coexpressed during embryonic and 
hematopoietic development[25, 26]. GATA-1 binds to 
FOG-1 and synergistically activates transcription from 
a hematopoietic-specific regulatory region[25-28]. We 
therefore detected the binding ability between GATA-
1 and FOG-1 following incubating with wogonin for 
48 hours (Figure 2C). The immunoprecipitation (IP) 
assay showed that wogonin enhanced the binding ability 
Oncotarget8190www.impactjournals.com/oncotarget
Figure 1: Cell cycle arrest induction and differentiation induction effects of wogonin on K562 and K562r cells. (A) Cell 
cycle analysis of K562 and K562r cells treated with 20, 40, and 80 μM wogonin for 48 hours was performed by flow cytometry. (B, C) The 
percentages of G0/G1 phase cells following wogonin treatment for 48 hours are shown. Data represent mean ± SEM from 3 independent 
experiments. (D) The percentages of cells expressing CD71 and GPA were detected by flow cytometry analyses. (E, F) The data represent 
the mean ± SEM of 3 different experiments. Asterisks denote statistically significant (P <0.05) differences compared with controls by one-
way ANOVA. (G) Benzidine-positive cells with brown-blue color were counted. The percentage was calculated based on 200 total cells per 
microscopic field and counting 5 times in each group. (H, I) GPA and γ-globin mRNA levels were detected by quantitative real-time reverse 
transcription-PCR and fold changes were normalized to β-actin. Asterisks denote significant (P <0 .05) differences compared to controls 
by two-tailed Student’s t test
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between GATA-1 and FOG-1, which was confirmed by 
real-time PCR analysis of α-globin, c-kit and GATA-2, the 
genes regulated by GATA-1 (Figure 2D). Therefore, it is 
concluded that wogonin induced erythroid differentiation 
by increasing expression of GATA-1 and FOG-1 and 
modulating DNA transcription via up-regulation of the 
binding of FOG-1 to GATA-1. 
Effect of GATA-1 on cell cycle in K562 and K562r 
cells
It is reported that GATA-1 binds to the promoter of 
p21 and activates its transcription[29-32]. To investigate 
the molecular mechanism of cell cycle arrest induced by 
wogonin, we examined the levels of the key checkpoints 
Figure 2: Wogonin regulates the expression of GATA-1 and p21 in K562 and K562r cells. (A) Expression levels of GATA-
1 and FOG-1 were analyzed by western blotting. Lamin A was used as a loading control. (B) EMSA assay detecting GATA-1 binding to 
its consensus site. Cells were incubated with wogonin for 48 hours and DNA binding was determined in nuclear extracts using EMSA. 
To determine the composition of the DNA-binding complex, the anti-GATA-1 antibody was used for supershift experiments. Data are 
representative of 3 separate experiments. (C) Cells incubated with/without 80 μM wogonin for 36 hours were immunoprecipitated with 
anti-GATA-1 antibody, followed by western blot analysis with anti-FOG-1 antibodies. (D) α-globin, c-kit and GATA-2 mRNA levels were 
detected by quantitative real-time PCR, and fold changes were assessed and shown normalized to β-actin. Asterisks denote significant (P 
<0 .05) differences relative to controls by two-tailed Student’s t test. (E) Expression levels of cyclin A, CDK4, cyclin D1 and p21 were 
analyzed by western blotting with β-actin as a loading control. Data are representative of 3 independent experiments.
Oncotarget8192www.impactjournals.com/oncotarget
of cell cycle progression in K562 and K562r cells. The 
ChIP experiment showed that the binding ability between 
GATA-1 and the promoter of p21 in both K562 and 
K562r cells enhanced when treated wogonin for 48 hours 
(Supplement figure 1). Also, cells treated with wogonin 
showed up-regulation of p21 (Figure 2E). Furthermore, 
wogonin treatment down-regulated cyclin-dependent 
kinase 4 (CDK4) and cyclin D1 (Figure 2E). These results 
showed that wogonin arrested cell cycle at G0/G1 phase 
by regulating GATA-1 associated cell cycle checkpoints 
in K562 cells.
Antiproliferative effects of wogonin in vivo
We next examined the effects of wogonin in vivo. 
15 days after injection with K562 and K562r cells, blood 
samples from three mice randomly in each group were 
examined for CD13 expression, a surface marker of K562 
cells. The results showed that mice inoculated K562 and 
K562r cells expressed more CD13 than normal mice and 
wogonin significantly decreased the expression of CD13 
in K562 and K562r group (Figure 3B-C). Wogonin also 
extended the survival of CML-bearing mice compared 
with mice in the control group (Figure 3A). The median 
survival time of mice injected with K562 and K562r cells 
were 27.8±2.91 and 19.5±2.7 days in the control groups 
and were 45±13.1 and 34.3±13.1 days in the wogonin-
treated groups. These results demonstrated that wogonin 
suppresses proliferation of K562 and K562r cells in vivo.
Effects of wogonin on differentiation of primary 
CML cells
Primary leukemic cells from CML patients were 
collected and used to investigate the effects of wogonin 
in CML cells. As shown in Figure 4A and 4B, expression 
of CD71 and GPA in CML cells increased following 
treatment with wogonin for 96 hours (Figure 4A-B). 
These data showed that wogonin induced differentiation 
in primary CML cells. The western blot results showed 
that the expression of GATA-1 increased in wogonin-
treated primary CML cells (Figure 4D). However, results 
Figure 3: Effects of wogonin on CML-bearing mice. (A) A Kaplan-Meier survival plots of CML-bearing NOD/SCID mice are 
shown. K562 and K562r cells were injected through tail vein 24 hours (2-5×106 cells per mouse, 6 mice per group) after sublethally 
irradiation (2.4 Gy). Data are representative of 2 separate experiments. Animals were observed for 60 days after cell injection. The survival 
curves differed significantly between the wogonin-treated group and the control group. Wogonin prolonged survival in mice compared with 
controls (P<0.001; log-rank test). (B) CD13 expression was examined in blood samples from three mice of each group. (C) Data represent 
the mean ± SEM of 3 different experiments. Asterisks denote statistically significant (P<0.05) differences compared with controls by one-
way ANOVA.
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of electrophoretic mobility shift assay (EMSA) showed 
no obvious difference between the control group and 
wogonin-treated group in the ability of DNA binding 
(Figure 4C). These results showed that GATA-1 has other 
effects on primary CML cells.
Wogonin regulates the effect of GATA-1 and 
inhibits phosphorylation of MEK and ERK in 
K562, K562r, and primary CML cells
We next investigated the mechanism by which 
wogonin inhibits proliferation of K562, K562r, and 
primary CML cells. We speculated that GATA-1 may 
inhibit cell proliferation through a non-transactivation 
mechanism. It is known that continued activation of the 
Philadelphia chromosome causes phosphorylation of 
downstream proteins such as MEK and ERK, resulting 
in activation of cell proliferation pathways[33, 34]. In 
addition, it has been reported that GATA-1 inhibits the 
MEK pathway by binding with MEK[35]. Therefore, 
we speculated that wogonin affects the binding ability 
between GATA-1 and MEK. Following treatment with 
wogonin for 36 hours, IP results showed that wogonin 
enhanced the binding ability between GATA-1 and MEK in 
Figure 4: Wogonin induces differentiation on primary CML cells and increases the interaction between GATA-1 and 
MEK. (A) The expression of CD71 and GPA was detected by flow cytometry analyses. Primary CML cells were treated with wogonin 
(40 and 80 μM) for 48 hours. (B) Quantification of the data shown in A. Data represented the mean ± SEM of 3 different experiments. 
Asterisks denote statistically significant (P <0.05) differences compared with controls by one-way ANOVA. (C) EMSA assay detected 
GATA-1 binding to its consensus site. Primary CML cells were incubated with wogonin for 48 hours, and DNA binding was determined 
in nuclear extracts using EMSA. To determine the composition of the DNA-binding complex, the anti-GATA-1 antibody was used for 
supershift experiments. Data are representative of 3 independent experiments. (D) Expression levels of GATA-1, MEK, p-MEK, ERK 
and p-ERK were analyzed by western blotting using indicated antibodies. β-actin was used as a loading control in primary CML cells. (E) 
Cells incubated with/without 80 μM wogonin for 36 hours were immunoprecipitated with anti-GATA-1 antibody, followed by western 
blot analysis with anti-MEK antibodies. (F) Expression levels of MEK, p-MEK, ERK and p-ERK were analyzed by western blotting using 
indicated antibodies. β-actin was used as a loading control.
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K562 and K562r cells (Figure 4E), and then we examined 
the phosphorylation of MEK and ERK in these two cell 
lines. The results showed that levels of phosphorylated 
MEK and ERK decreased following incubation with 
wogonin (Figure 4F). The primary CML cells treated with 
wogonin for 48 hours also showed notable reduction of 
phosphorylated MEK and ERK (Figure 4D). These results 
suggested that, apart from increasing expression of p21 
and promoting DNA binding, wogonin increased protein 
expression of MEK and ERK by enhancing the binding 
ability between GATA-1 and MEK.
Figure 5: GATA-1 is involved in wogonin-modulated growth inhibition and differentiation. (A) Following siRNA 
transfection, K562 and K562r cells were treated with or without wogonin for 96 hours. Confirmation of the silencing of GATA-1 expression 
was detected by western blotting with β-actin as a loading control. (B) Growth inhibition of wogonin was assessed by MTT assay. (C) CD71 
and GPA-positive cells were measured by flow cytometry. (D) The data represent the mean ± SEM of 3 different experiments. Asterisks 
denote statistically significant (P <0.05) differences compared with controls by one-way ANOVA. 
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Role of GATA-1 in wogonin-induced 
differentiation and cycle arrest effect on K562 and 
K562r cells
To better understand the role of GATA-1 in 
wogonin-induced differentiation and cell cycle arrest, 
we transfected the siRNA of GATA-1 into K562 and 
K562r cells and monitored efficacy of transfection using 
western blot assays. Results of MTT assay showed that 
GATA-1 siRNA partially reduced wogonin-induced cell 
proliferation inhibition (Figure 5B). After silencing GATA-
1 (Figure 5A), wogonin-induced expression of CD71 and 
GPA in K562 and K562r cells decreased (Figure 5C-D). 
In the same way, with the GATA-1 silence, the effect of 
wogonin on cell cycle arrest was also inhibited (Figure 
6A-B). Meanwhile, the regulative effect of wogonin on the 
levels of cell cycle regulators were also reduced (Figure 
6C). These data suggested that GATA-1 is required for 
wogonin-induced cell differentiation and cell cycle arrest.
Figure 6: GATA-1 is involved in wogonin-modulated cycle arrest. (A) The percentages of cells in G0/G1 phases of the cell cycle 
are shown. (B) Data represent the mean ± SEM of 3 different experiments. Asterisks denote statistically significant (P <0.05) differences 
compared with controls by one-way ANOVA. (C) Effect of silencing GATA-1 on the expression of cell cycle checkpoint proteins.
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DISCUSSION
Treatment of leukemia by forcing malignant cells 
to undergo differentiation instead of being killed by 
cytotoxic drugs is a promising alternative therapeutic 
strategy for leukemia, which has been previously applied 
for treatment of AML[36, 37]. In this study, we found 
an interesting phenomenon that wogonin could induce 
erythroid differentiation in K562 cells and primary CML 
cells, demonstrated by the benzidine staining assay and 
increased level of CD71 and GPA. 
GATA-1 is a transcription factor that regulates 
cellular differentiation and proliferation[38, 39]. It 
is initially discovered as a nuclear protein that binds 
numerous GATA consensus motifs distributed throughout 
various enhancers and promoters of erythroid-specific 
genes[38]. Moreover, GATA-1 is also a key regulator 
of erythropoiesis, and inhibition of GATA-1 decrease 
the erythropoietic effect of EPO[40]. The essential 
GATA-1 cofactor FOG-1 is required for differentiation 
of erythrocytes, and recent studies have shown that 
FOG-1 promotes GATA-1 transcription activity not 
only by recruiting coactivators, but also by directly 
modulating chromatin occupancy[38, 41]. Our results 
demonstrated that wogonin enhances DNA binding of 
GATA-1 and recruits FOG-1, resulting in increased 
expression of erythroid-specific genes, leading to 
erythroid differentiation. The results of siRNA confirmed 
that GATA-1 has an important role in wogonin-induced 
erythroid differentiation. GATA-1 is the key factor 
involved in wogonin-induced differentiation. There 
are many factors that affect the expression of GATA-1 
including the GATA-1/GATA-2 switch effect[41]. Other 
signaling pathways, such as the PI3K/AKT pathway, may 
regulate the phosphorylation and subsequent activity of 
GATA-1. It is previously reported that wogonin has the 
ability to activate the PI3K/AKT pathway[42]. Further 
studies are required to study whether wogonin regulates 
erythroid differentiation through other signaling pathways.
Cell cycle arrest is an essential early event in 
inducing differentiation. Therefore, we detected the cell 
cycle arrest effect of wogonin on K562 cells. Also, we 
focused on the effect of GATA-1 in cell cycle arrest. 
Previous research showed that GATA-1 binds to the 
promoter of p21 and activates the expression of p21 and its 
downstream proteins[29]. Our data showed that wogonin 
arrested the cell cycle following 48 hours treatment by 
enhancing the binding ability between GATA-1 and the 
promoter of p21 and then promoted the expression of p21.
We had demonstrated that wogonin induced 
erythroid differentiation and cycle arrest and found that 
wogonin had these effects via regulating the function of 
GATA-1. In vivo results showed that wogonin prolonged 
the survival of mice injected with CML cells by inhibiting 
proliferation of K562 cells. Our investigation indicated 
that wogonin inhibited proliferation of K562 cells via 
GATA-1. Wogonin increased the binding ability of MEK 
and GATA-1, inhibiting the activation of the MEK-ERK 
pathway[35]. GATA-1 inhibits phosphorylation of ERK 
by interacting with MEK, which is upstream of ERK, and 
the phosphorylation of ERK inhibits cell proliferation[35]. 
It has been reported that MEK contains a nuclear export 
signal in its N-terminal domain, indicating that MEK 
works in the nucleus for signaling purposes, and then 
returns to the cytoplasm. GATA-1 binds with MEK in the 
nucleus and inhibits its activity[43]. Wogonin increased 
the binding ability between GATA-1 and MEK, and then 
inhibited phosphorylation of MEK. Therefore, we knew 
that, GATA-1 is the key factor in wogonin’s effect on 
K562 cells. 
We further examined the effect of GATA-1 on 
primary CML cells. Our studies showed that levels of 
phosphorylated MEK and ERK in primary CML cells 
were higher than those in K562 cells, and wogonin 
showed a more inhibitory effect on phosphorylation of 
MEK and ERK in primary CML cells (Data not shown). 
This difference might be due to the fact that the primary 
cells used in the current study were blast crisis cells. 
Although K562 is a blast crisis cell line, the primary cells 
may show a stronger ability in proliferation. Therefore, 
primary cells have aberrant copy numbers of BCR-ABL, 
which is likely to provide stronger survival signaling[10]. 
Finally, wogonin did not affect DNA binding in primary 
CML cells, which was totally different from the activity in 
K562 cells, suggesting that GATA-1 plays a different role 
under different cellular environments.
Depart from K562 cells we also focused on the 
effect of wogonin on K562r cells. Drug-resistance 
presents a significant problem when using imatinib for 
the treatment of CML patients. The resistance of CML 
to imatinib treatment mostly manifests as decreased drug 
uptake and mutation of the BCR-ABL fusion gene[5]. 
Although the second generation TKIs, such as nilotinib 
and dasatinib, appear to be effective in imatinib-resistant 
patients, these drugs are also TKIs, it is possible for these 
drugs appear the similar resistance with imatinib, and 
therefore new treatment strategies are needed urgently[5, 
9, 44]. Recently, results from the ‘non-randomized 
stop IM’ trial showed that 61% of CML patients who 
discontinued imatinib after achieving a complete 
molecular remission eventually relapsed[10, 11]. For 
example, the Hsp90 inhibitor geldanamycin selectively 
sensitizes Bcr-Abl-expressing leukemia cells[12]. The 
mechanism by which wogonin inhibits proliferation 
of CML cells is totally different from that of imatinib, 
which offers a possibility that wogonin may be effective 
in imatinib-resistant CML. Our in vivo and in vitro data 
showed that wogonin induced differentiation and cell 
cycle arrest in K562r cells, inhibited cell proliferation, and 
extended lifespan of K562r-bearing mice. These findings 
strongly suggested that wogonin may be an alternative 
drug for treatment avoiding the drug-resistance problem 
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associated with TKIs. 
In conclusion, our study showed that wogonin 
induced erythroid differentiation and cell cycle arrest 
in CML cells via regulating the function of GATA-
1. Wogonin increased the expression of GATA-1 then 
activated transcription and promoted the expression of 
p21 and enhanced the binding ability between GATA-1 
and MEK. Additionally, wogonin significantly prolonged 
survival of CML-bearing mice by inhibiting proliferation 
of K562 and K562r cells. These data suggested that 
wogonin is a potent drug for treatment of CML. Moreover, 
because its mechanisms of action differ from those of 
TKIs, wogonin may provide an alternative for TKI-
resistance CML. In this study, we found that the dosage is 
high both in vivo and in vitro, we think that wogonin may 
become an assist drug for CML and combine with TKIs.
MATERIALS AND METHODS
Reagents and antibodies
Wogonin (purity ≥99%) was synthesized and used 
in all experiments unless otherwise indicated[45]. The 
final concentration of dimethyl sulfoxide (DMSO) in all 
experiments was ≤0.01%, and cells treated with the highest 
concentration of DMSO were used as controls in the 
corresponding experiments. Heat-inactivated fetal bovine 
serum (FBS), and RPMI 1640 medium were purchased 
from Gibco Invitrogen Corporation (Carlsbad, CA, USA). 
PE anti-human CD71 (Transferrin Receptor), APC anti-
human Glycophorin A (CD235a) and FITC anti-human 
CD13 antibodies were purchased from eBioscience (San 
Diego, CA, USA). Antibodies against GATA-1, FOG-
1, MEK, ERK, p-ERK (Thr 177/160), and β-actin were 
purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA), and antibodies against p-MEK (Ser 217/221) 
were purchased from Cell Signaling Technology (Danvers, 
MA, USA). IRDyeTM 800-conjugated secondary 
antibodies were obtained from Rockland (Philadelphia, 
PA, USA).
Cell culture
The K562 cell line was purchased from the cell bank 
of Shanghai Institute of Biochemistry and Cell Biology. 
Imatinib-resistant K562 cells were kindly provided by 
Professor Junia V. Melo, Department of Pathophysiology, 
Chemical Biology Division of Shanghai Universities 
E-Institutes, Key Laboratory of Cell Differentiation and 
Apoptosis of the National Ministry of Education. Primary 
leukemic cells from CML blast crisis patients (Zhongda 
Hospital of Southeast University, Nanjing, China) were 
collected using lymphocyte-monocyte separation medium 
(Jingmei, Nanjing, China). The protocol of collection 
of cells from patients complied with guidelines in 
the Declaration of Helsinki, and was approved by the 
Institutional Review Board of Zhongda Hospital. A signed 
informed consent was obtained from each patient. Primary 
leukemic cells and K562/K562r cell lines were cultured 
with RPMI 1640 medium supplemented with 10% FBS.
Cell cycle analysis
The cell cycle analysis was employed by propidium 
iodide staining and quantified by a FACS Calibur flow 
cytometer (Becton, Dickinson, San Jose, CA, USA)[46]. 
The percentage of cells in each phase of the cell cycle was 
analyzed with Modfit software (Becton, Dickinson, San 
Jose, CA, USA).
Animal model 
Animal studies were conducted in accordance 
with the regulations of the China Food and Drug 
Administration (CFDA) on Animal Care. Female NOD/
SCID immunodeficient mice (aged 6–9 weeks) were 
purchased from Beijing HFK bioscience Company 
Limited. The mice were maintained in an air-conditioned 
pathogen-free room under conditions of controlled lighting 
(12 h light/day) and fed a standard diet of laboratory food 
and water. These immunodeficient mice were sublethally 
irradiated (2.4 Gy), and were injected with K562, K562r, 
or primary CML cells via the tail vein (2–5 × 106 cells 
per mouse, n = 6 per group) in 24 hours following the 
radiation treatment. Animals in the control group were 
injected with Physiological saline to evaluate the effects 
of injection on survival. The next day, the mice were 
injected intraperitoneally (i.p.) with or without wogonin 
(80 mg/kg) every other day for 14 days[42]. Following 
i.p. injection, the animals in K562 and K562r groups were 
inspected daily for 80 days, the animals in primary CML 
group were inspected daily for 30 days, and survival was 
represented using a Kaplan-Meier survival plot. 
Cell proliferation assays in vivo
In vivo investigations were performed using 
immunodeficient (NOD/SCID) mice engrafted with, 
K562, K562r, or primary human CML cells. Twenty days 
later, blood of the NOD/SCID mice was collected and the 
expression of CD13, a marker of K562, was examined 
by flow cytometry with a FACS Calibur flow cytometer 
(Becton, Dickinson, San Jose, CA, USA). 
Cell differentiation analysis
Cells (5 × 104 cells/mL) were incubated with 
different concentrations of wogonin in 6-well flat bottom 
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plates for 5 days. Following incubation, the cells were 
collected and washed twice with PBS, stained with 
benzidine solution containing 3% H2O2 for 30 min, 
followed by addition 0.6 mL of 10% ethanoic acid[47]. 
Cells displaying brown-blue color after staining were 
regarded as erythroid differentiation positive cells. The 
experiment was conducted in triplicate. Expression of the 
cell surface differentiation markers GPA and CD71 was 
determined by flow cytometry with a FACS Calibur flow 
cytometer (Becton, Dickinson, San Jose, CA, USA).
Western blot analysis 
The Western blot analysis was prepared as described 
previously[48]. Cells were collected and lysed in lysis 
buffer (50 mM Tris-Cl, pH 7.6, 150 mM NaCl, 1 mM 
EDTA, 1% (m/v) NP-40, 0.2 mM phenylmethanesulfonyl 
fluoride (PMSF), 0.1 mM NaF, and 1.0 mM dithiothreitol). 
The lysates were centrifuged at 13,000 × g and 4 °C for 
15 min. Protein concentrations in the supernatants were 
measured using a bicinchoninic acid (BCA) assay kit 
(Pierce, Rockford, IL, USA) by a Varioskan multimode 
microplate spectrophotometer (Thermo Waltham, MA, 
USA). Equal amounts of protein (50 μg) were separated 
by 8-12% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred onto PVDF 
membranes (Millipore, Boston, MA, USA). The blots 
were then incubated with primary antibodies for overnight 
at 4°C, followed by incubation with IRDyeTM800 
conjugated secondary antibody for 1 h at 37°C. Detection 
was performed using the Odyssey Infrared Imaging 
System (LI-COR Inc, Lincoln, NE, USA).
Immunoprecipitation
Supernatants of cell lysates were incubated with 
GATA-1 antibody for 1 h at 4 °C, and then added 20 μl of 
protein G/A agarose beads (Santa Cruz Biotechnology, St. 
Louis Park, Minnesota, US) overnight at 4 °C. Beads were 
washed with cell lysis buffer 4 times and bound proteins 
were eluted with 2× loading sample buffer and analyzed 
by Western blot with indicated antibodies.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared and electrophoretic 
mobility shift assay was conducted according to the 
manufacturer’s instructions (EMSA kit; Beyotime, 
Nanjing, China)[49].
Quantitative real-time reverse transcription-
polymerase chain reaction (RT-PCR)
The RT-PCR assay was prepared as described 
previously[48]. For quantitative analysis of gene 
expression, total RNA was isolated using a TRIzol kit 
(Invitrogen, Carlsbad, CA, USA). Complementary DNA 
was synthesized using a complementary DNA synthesis 
kit (Code DRR047A; TaKaRa, Kyoto, Japan) according 
to the manufacturer’s instructions. Relative quantities of 
mRNA were measured using Applied Biosystems 7500 
Fast Real-Time PCR System (PerkinElmer, Torrance, CA, 
USA) and double-stranded DNA dye SYBR Green PCR 
core reagents (Code DRR081C; TaKaRa, Kyoto, Japan). 
Amplification was performed with 40 cycles at 95°C for 
15 seconds and then at 60°C for 30 seconds. Data were 
analyzed using 7500 system SDS software.
Statistical analysis
All data are expressed as the mean ± standard error 
of the mean (SEM) for the values obtained from at least 
three independent experiments. Statistical analysis of 
multiple-group comparisons was performed by one-way 
analysis of variance (ANOVA) followed by the Bonferroni 
posthoc test. Comparisons between two groups were 
analyzed using the two-tailed Student’s t-test. The survival 
of NOD/SCID mice was evaluated by Kaplan-Meier 
analysis using the log-rank test to compare differences. P 
value <0.05 was considered statistically significant.
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